Literature DB >> 33186593

Traditional and modern management strategies for rheumatoid arthritis.

Muhammad Akram1, Muhammad Daniyal2, Sabira Sultana3, Aymen Owais4, Naheed Akhtar5, Rabia Zahid3, Fahad Said6, Abdelhakim Bouyahya7, Evgeny Ponomarev8, Mohammad Ali Shariat8, Muthu Thiruvengadam9.   

Abstract

Rheumatoid arthritis (RA) is a serious disorder of the joints affecting 1 or 2% of the population aged between 20 and 50 years worldwide. RA is the foremost cause of disability in developing and Western populations. It is an autoimmune disease-causing inflammation and pain involving synovial joints. Pro-inflammatory markers, including cytokines, such as interleukin -1 (IL-1), IL-6, IL-7, IL-8, and tumor necrosis factor-α (TNF-α) are involved in RA. RA treatment involves TNF-α blockade, B cell therapy, IL-1 and IL-6 blockade, and angiogenesis inhibition. Synthetic drugs available for the treatment of RA include disease-modifying anti-rheumatic drugs (DMARD), such as cyclophosphamide, sulfasalazine, methotrexate, nonsteroidal anti-inflammatory drugs (NSAIDs), and intramuscular gold. These agents induce adverse hepatorenal effects, hypertension, and gastric ulcers. We found that patients diagnosed with chronic pain, as in RA, and those refractory to contemporary management are most likely to seek traditional medicine. Approximately 60-90% of patients with arthritis use traditional medicines. Therefore, the efficacy and safety of these traditional medicines need to be established. The treatment for RA entails a comprehensive multidisciplinary strategy to reduce pain and inflammation and to restore the activity of joints. The potential medicinal plants exhibiting anti-arthritic and anti-rheumatic pharmacological activity are reviewed here.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-arthritic potential; Management of arthritis; Rheumatoid arthritis; Traditional medicines

Mesh:

Substances:

Year:  2020        PMID: 33186593     DOI: 10.1016/j.cca.2020.11.003

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

Review 1.  Overview of First-Line and Second-Line Pharmacotherapies for Osteoarthritis with Special Focus on Intra-Articular Treatment.

Authors:  Alicja Nowaczyk; Dawid Szwedowski; Ignacio Dallo; Jacek Nowaczyk
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

2.  Determination of Therapeutic and Safety Effects of Zygophyllum coccineum Extract in Induced Inflammation in Rats.

Authors:  Mohammed Yosri; Mahmoud M Elaasser; Marwa M Abdel-Aziz; Marwa M Hassan; Abdulmohsen Hussen Alqhtani; Naif Al-Gabri; Ahmed B A Ali; A Pokoo-Aikins; Basma H Amin
Journal:  Biomed Res Int       Date:  2022-07-18       Impact factor: 3.246

3.  Anti-TNF-α agents for refractory intestinal Behçet's disease: case series and meta-analysis.

Authors:  Shukai Zhan; Caiguang Liu; Na Li; Tong Li; Zhenyi Tian; Min Zhao; Dongxuan Wu; Minhu Chen; Zhirong Zeng; Xiaojun Zhuang
Journal:  Therap Adv Gastroenterol       Date:  2022-09-03       Impact factor: 4.802

4.  In vitro activity of anti-rheumatic drugs on release of pro-inflammatory cytokines from oral cells in interaction with microorganisms.

Authors:  Alexandra Stähli; Carina Scherler; Graziano Zappalà; Anton Sculean; Sigrun Eick
Journal:  Front Oral Health       Date:  2022-09-02

5.  Immune Effects of Macrophages in Rheumatoid Arthritis: A Bibliometric Analysis From 2000 to 2021.

Authors:  YunLing Xu; Zhongmin Zhang; Jiaolong He; Zhenxing Chen
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

6.  The use of LED therapy to treat synovial joints disorders: scoping review.

Authors:  Camila Amaral Coracini; Francyelle Dos Santos Soares; Gladson Ricardo Flor Bertolini
Journal:  Lasers Med Sci       Date:  2021-07-14       Impact factor: 3.161

7.  Inter-alpha-trypsin inhibitor heavy chain 4: A serologic marker relating to disease risk, activity, and treatment outcomes of rheumatoid arthritis.

Authors:  Kejian He; Sanshan He; Min Su
Journal:  J Clin Lab Anal       Date:  2022-01-22       Impact factor: 2.352

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.